These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6838048)

  • 21. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of chronic dosing on theophylline clearance.
    Efthimiou H; Morgan DJ; Ioannides-Demos L; Raymond K; McLean AJ
    Br J Clin Pharmacol; 1984 May; 17(5):525-30. PubMed ID: 6733000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal variation in the disposition of theophylline and its metabolites.
    St-Pierre MV; Spino M; Isles AF; Tesoro A; MacLeod SM
    Clin Pharmacol Ther; 1985 Jul; 38(1):89-95. PubMed ID: 4039998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rifampin on theophylline disposition.
    Straughn AB; Henderson RP; Lieberman PL; Self TH
    Ther Drug Monit; 1984; 6(2):153-6. PubMed ID: 6740733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.
    Bachmann K; White D; Jauregui L; Schwartz JI; Agrawal NG; Mazenko R; Larson PJ; Porras AG
    J Clin Pharmacol; 2003 Oct; 43(10):1082-90. PubMed ID: 14517190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug disposition in cystic fibrosis.
    Rey E; Tréluyer JM; Pons G
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probenecid pharmacokinetics in cystic fibrosis.
    Weber A; de Groot R; Ramsey B; Williams-Warren J; Smith A
    Dev Pharmacol Ther; 1991; 16(1):7-12. PubMed ID: 1879255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
    Wiessmann KJ
    Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theophylline kinetics: dose dependency and single sample prediction of clearance.
    Bachmann K; Schwartz J; Forney R; Jauregui L
    Pharmacology; 1985; 30(3):136-44. PubMed ID: 3975263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic studies on proxyphylline administered intravenously and orally to man.
    Graffner C; Johnsson G; Sjögren J
    Acta Pharm Suec; 1973 Dec; 10(6):425-34. PubMed ID: 4773111
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and bronchodilatory effect of proxyphylline and theophylline.
    Rasmussen FV; Waldorff S; Madsen L
    Eur J Respir Dis; 1984 Jan; 65(1):20-7. PubMed ID: 6705854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability of theophylline clearance in determining chronic oral dosage regimens.
    Slotfeldt ML; Johnson CE; Grambau G; Weg JG
    Am J Hosp Pharm; 1979 Jan; 36(1):66-8. PubMed ID: 758787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of oral dose of oxtriphylline to serum theophylline level.
    Guyatt GH; Desai SD
    Can Med Assoc J; 1981 Dec; 125(12):1336-8. PubMed ID: 7034918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid methylprednisolone clearance in a patient with cystic fibrosis.
    Green CG; Kraus CK; Lemanske RF; Farrell PM; Jusko WJ
    Drug Intell Clin Pharm; 1988 Nov; 22(11):876-8. PubMed ID: 3234253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.
    Jones KM; Liao E; Hohneker K; Turpin S; Henry MM; Selinger K; Hsyu PH; Boucher RC; Knowles MR; Dukes GE
    Pharmacotherapy; 1997; 17(2):263-70. PubMed ID: 9085317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Theophylline disposition in patients with hepatic cirrhosis.
    Piafsky KM; Sitar DS; Rangno RE; Ogilvie RI
    N Engl J Med; 1977 Jun; 296(26):1495-7. PubMed ID: 865528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of dibekacin in children with cystic fibrosis.
    Courcol RJ; Loeuille GA; Delnatte J; Martin GR
    Int J Clin Pharmacol Res; 1985; 5(2):87-91. PubMed ID: 4018945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.
    Denlinger CL; Stryker KK; Slusher LB; Vesell ES
    Clin Pharmacol Ther; 1987 May; 41(5):522-30. PubMed ID: 3568537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Theophylline in childhood asthma. Pharmacokinetic and clinical study (author's transl)].
    Bellon G; Plasse JC; Satta S; Barbier Y; Gilly R
    Rev Fr Mal Respir; 1981; 9(2):113-21. PubMed ID: 7255850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.